Thermo Fisher Scientific Launches New CXCL10 Testing Service
02 Mayo 2024 - 7:15AM
Business Wire
Noninvasive urine-based biomarker testing can
support routine testing for graft dysfunction
For organ transplant recipients, life post-transplant involves a
delicate balance between invasive monitoring and immunosuppression
to reduce the risk of rejection, both of which may carry
complications. Now, a simple, urine-based assay that detects the
CXCL10 chemokine may make care more convenient and less invasive
for the nearly 250,000 Americans living with a kidney
transplant.
Thermo Fisher Scientific One Lambda Laboratories, a CLIA
facility in Fishers, Ind., has introduced a new CXCL10 testing
service, which allows for non-invasive urine sample collection and
testing, with results available in as little as 24 hours, providing
valuable information faster than currently used tests. Multiple
studies have shown that elevated urinary CXCL10 levels are
associated with inflammation and early kidney transplant rejection,
as outlined in a recent article in Current Opinion in Organ
Transplantation.
“Current methods of post-transplant monitoring can represent a
significant financial and physical burden for many transplant
patients. In keeping with our commitment to health equity, we
believe this lower-cost, non-invasive testing option can expand
access to care and improve patient adherence, since the sample can
be collected at any local clinic,” says Chris McCloskey, director,
Transplant Services, Thermo Fisher Scientific.
Thermo Fisher’s CXCL10 testing service may supplement current
standards of care that may lack specificity or sensitivity, which
may lead to unnecessary and invasive biopsies, or produce results
too late to influence care, making treating rejection more
difficult. This can lead to an aggressive immunosuppression regime,
increasing patient morbidity and mortality risks.
“We’ve heard directly from patients that invasive biopsies and
aggressive immunosuppression to prevent rejection can be incredibly
detrimental to their physical and mental health. That’s why we’re
proud to be at the forefront of industry, leading the way with new
non-invasive tests designed to improve patient outcomes and quality
of life throughout the transplant journey,” adds Tina Liedtky,
president, Transplant Diagnostics, Thermo Fisher Scientific.
Learn more at Thermo Fisher Scientific One Lambda CXCL10 Testing
Services.
The Thermo Fisher One Lambda Laboratories CXCL10 assay was
developed and validated by One Lambda Laboratories. This laboratory
developed test (LDT) is used for clinical purposes by the
CLIA-certified laboratory performing the test. This test has not
been cleared or approved by the FDA as an in vitro diagnostic
test.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with annual revenue over $40 billion. Our Mission is to
enable our customers to make the world healthier, cleaner and
safer. Whether our customers are accelerating life sciences
research, solving complex analytical challenges, increasing
productivity in their laboratories, improving patient health
through diagnostics or the development and manufacture of
life-changing therapies, we are here to support them. Our global
team delivers an unrivaled combination of innovative technologies,
purchasing convenience and pharmaceutical services through our
industry-leading brands, including Thermo Scientific, Applied
Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services,
Patheon and PPD. For more information, please visit
www.thermofisher.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502060655/en/
Media Contact Information: Amber Gabrenas 760-681-6678
amber.gabrenas@thermofisher.com